Role and Relevance of Proton-Coupled Oligopeptide Transporters in the Brain
University of Maryland CERSI in Collaboration with CDER/OTS/OCP
Monday, June 26, 2017
David E. Smith, Ph.D.
John G. Wagner Collegiate Professor
Department of Pharmaceutical Sciences
College of Pharmacy
The University of Michigan
Ann Arbor, Michigan
About the Presenter
Dr. Smith is the John G. Wagner Collegiate Professor of Pharmaceutical Sciences at the University of Michigan, College of Pharmacy, and a member of the Comprehensive Cancer Center and Michigan Gastrointestinal Peptide Research Center in the School of Medicine. He served as Founding Chair, Department of Pharmaceutical Sciences, from 1999-2010. Dr. Smith received his B.S. in Pharmacy (1975) from the State University of New York at Buffalo and his Ph.D. in Pharmaceutical Chemistry (1981) from the University of California San Francisco. Dr. Smith is a Fellow of the American Association of Pharmaceutical Scientists (1998) and the American Association for the Advancement of Science (2012), and served on the Pharmacology Study Section of the National Institutes of Health (1998-2002). He has received numerous awards including the James R. Gillette Drug Metabolism and Disposition Best Paper Award from the American Society for Pharmacology and Experimental Therapeutics on two separate occasions (2002 and 2008). Dr. Smith is a member of several scientific and professional organizations (e.g., AAAS, AACP, AAPS, APhA, ASPET, ISSX) and is an Editor of Pharmaceutical Research. During his career, he has made many important scientific contributions, including those on the kinetic-dynamic relationship of loop diuretics, the determinants of renal drug elimination, the regional pharmacokinetics of anticancer drugs, and the cellular and molecular biology, physiology and pharmacology of proton-coupled oligopeptide transporters.
Drug transporters have been widely studied for their physiological, pharmacological and toxicological relevance in select organs for improved delivery and targeting of substrates in the intestine, kidney, liver and brain. Some of these transporters, however, make drug delivery to these organs more difficult because of their role in efflux as opposed to influx. In this presentation, Dr. Smith gave a general overview of drug transporters in the brain and, more specifically, to his newest research on the role and relevance of proton-coupled oligopeptide transporters (PepT2 and PhT1) in this sanctuary tissue.
Please contact Lei K. Zhang at LeiK.Zhang@fda.hhs.gov